参考文献/References:
［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019［J］. CA Cancer J Clin, 2019, 69: 7-34.
［2］ Forner A, Reig M, Bruix J. Hepatocellular carcinoma［J］. Lancet,2018, 391:1301-1314.
［3］ Wang A, Wu L, Lin J,et al. Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma［J］. Nat Commun, 2018, 9:894.
［4］ Chang Lee R, Tebbutt N. Systemic treatment of advanced hepatocellular cancer: new hope on the horizon［J］. Expert Rev Anticancer Ther, 2019, 19:343-353.
［5］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics,2012［J］. CA Cancer J Clin, 2015, 65: 87-108.
［6］ Reynolds AR, Furlan A, Fetzer DT, et al. Infiltrative hepatocellular carcinoma: what radiologists need to know［J］. Radiographics, 2015: 371-386.
［7］ Khalaf MH, Sundaram V, Abdelrazek MM, et al. A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma［J］. Radiology, 2019, 290: 254-261.
［8］ Lv N, Kong Y, Mu L, et al. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterialhemoembolization for inoperable hepatocellular carcinoma: aprospective randomized trial［J］. Eur Radiol, 2016, 26: 3492-3499.
［9］ Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations［J］. J Magn Reson Imaging, 2003, 18: 189-195.
［10］ Yau T, Tang V, Yao TJ, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma［J］. Gastroenterology, 2014, 146: 1691-1700.
［11］ Dai QS, Gu HL, Ye S, et al. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: a retrospective comparative study［J］. Mol Clin Oncol,2014, 2: 1047-1054.
［12］ Jang ES, Yoon JH, Chung JW, et al. Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization［J］. J Cancer Res Clin Oncol, 2013, 139: 635-643.
［13］ Lee SH, Hahn ST, Park SH. Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma: its effectiveness and optimal timing of administration［J］. Cardiovasc Intervent Radiol, 2002, 24: 368-371.
［14］ Nault JC, Nkontchou G, Nahon P, et al. Percutaneous treatment of localized infiltrative hepatocellular carcinoma developing on cirrhosis［J］. Ann Surg Oncol, 2016, 23: 1906-1915.
［15］ Duan F, Bai YH, Cui L, et al. Transarterial embolization with N-butyl 2-cyanoacrylate for the treatment of arterioportal shunts in patients with hepatocellular carcinoma［J］. J Cancer Res Ther, 2017, 13: 631-635.
［16］Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication,and patient selection［J］. J Hepatol, 2015, 62: 1187-1195.
［17］ Masada T, Tanaka T, Nishiofuku H, et al. Techniques to form a suitable lipiodol-epirubicin emulsion by using 3-way stopcock methods in transarterial chemoembolization for liver tumor［J］. J Vasc Interv Radiol, 2017, 28: 1461-1466.
［18］ Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs［J］. Am J Hosp Pharm, 1983, 40: 1159-1160.
［19］王振华. 利多卡因硬膜外麻醉意外法医毒物动力学研究（八）［D］. 太原：山西医科大学，2008．
［20］王天成，马 聪，肖煜东，等. 利多卡因-表柔比星-超液化碘油混合乳剂在肝癌TACE相关疼痛管理中的应用［J］. 介入放射学杂志，2020，29：366-371．
［21］李 军，裘敏剑，章士正. 肝癌经导管动脉栓塞化疗术中利多卡因碘油乳剂止痛效果评价［J］. 全科医学临床与教育，2011，9：431-432．
［22］陈丽霞，杨永明，魏锦萍，等. 利多卡因对丝裂霉素治疗肝癌H22荷瘤小鼠的增敏作用研究［J］. 肿瘤研究与临床，2019，31：84-87．
［23］曾志宏，王 奕，胡含明，等. 利多卡因-碘油乳剂在原发性肝癌介入栓塞治疗中的临床应用［J］. 中国中西医结合影像学杂志，2009，7：151-152．
［24］王小会，鲁 岩. 利多卡因碘油乳剂在经导管动脉内化疗栓塞中的止痛效果评价［J］. 肿瘤基础与临床，2011，24：224-246．
［25］ Wang Y, Ou-Yang QG, Huang WL, et al. Investigation of the inhibitory effect of simvastatin on the metabolism of lidocaine both in vitro and in vivo［J］. Drug Des Devel Ther, 2020, 14:1739-1747.